We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Mark Emberton

Mark Emberton MD, FRCS, OBE, FMedSci

Professor of Interventional Oncology and Director, Division of Surgery and Interventional Science, University College London; Honorary Consultant Urologist, University College Hospital, London, United Kingdom

Dr. Mark Emberton holds the post of Professor in Interventional Oncology at University College London. He is the Director, Division of Surgery and Interventional Science at UCL. He holds the position of Pathway Director for Urological Cancer for London Cancer—an integrated cancer system serving the residents of North London. He is also Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. His clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In the area of prostate cancer, much of his activity is, at present, focused on evaluating minimally invasive therapies for localized disease. This work encompasses the precise characterization of disease as well as targeting therapies. He is also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomized control trial in surgery. He is involved in guideline development and appraisal and is interested in the formulation of evidence-based management policies. He is an active researcher, has lectured widely, and has published over 200 peer-reviewed articles in numerous scientific journals.